234 results on '"Kraemer, Alwin"'
Search Results
2. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
3. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
4. Synthetic patches, real images: screening for centrosome aberrations in EM images of human cancer cells
5. Author Reply to Peer Reviews of STIL overexpression shortens lifespan and reduces tumor formation in mice
6. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
7. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
8. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
9. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
10. STIL overexpression shortens lifespan and reduces tumor formation in mice
11. Enasidenib
12. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
13. Diagnostic Work-up of CUP: An Approach to Current Recommendations and Underlying Evidence
14. Future Directions
15. Prognostic Factors and Their Role in the Management of CUP
16. Biologic Features of CUP
17. Introduction
18. Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability
19. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
20. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
21. Mechanisms and Consequences of Centrosome Clustering in Cancer Cells
22. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
23. Centrosomes in Checkpoint Responses
24. Stammzellentherapie — Frischzellentherapie der Zukunft?
25. A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
26. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
27. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution
28. Mechanism of Carcinogenesis by Polycyclic Aromatic Hydrocarbons: Aneuploidy precedes malignant transformation and occurs in all cancers
29. Centrosome amplification in tumorigenesis
30. Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
31. Microcephalin and Pericentrin Regulate Mitotic Entry via Centrosome-Associated Chk1
32. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
33. Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
34. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
35. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial
36. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells
37. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma
38. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
39. RAS activation and CDKN2A deletion to predict prognosis in cancer of unknown primary.
40. Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia
41. Aneuploidy Precedes and Segregates with Chemical Carcinogenesis
42. Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
43. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
44. A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations
45. High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia
46. Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo
47. Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia
48. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations
49. Impact of KMT2A-PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation
50. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.